The US FDA approved Susvimo™ for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, AMD who have previously responded to at least two anti-VEGF injections.
[Genentech]
7992332
{7992332:nan}
apa
50
1
168179
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/